Cargando…
An Intrabody Drug (rAAV6-INT41) Reduces the Binding of N-Terminal Huntingtin Fragment(s) to DNA to Basal Levels in PC12 Cells and Delays Cognitive Loss in the R6/2 Animal Model
Huntington's disease (HD) is a fatal progressive disease linked to expansion of glutamine repeats in the huntingtin protein and characterized by the progressive loss of cognitive and motor function. We show that expression of a mutant human huntingtin exon-1-GFP fusion construct results in nons...
Autores principales: | Amaro, I. Alexandra, Henderson, Lee A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995342/ https://www.ncbi.nlm.nih.gov/pubmed/27595037 http://dx.doi.org/10.1155/2016/7120753 |
Ejemplares similares
-
rAAV/ABAD-DP-6His attenuates oxidative stress-induced injury of PC12 cells
por: Jia, Mingyue, et al.
Publicado: (2014) -
Robust Long-term Transduction of Common Marmoset Neuromuscular Tissue With rAAV1 and rAAV9
por: Okada, Hironori, et al.
Publicado: (2013) -
Differential effects of two MRI contrast agents on the integrity and distribution of rAAV2 and rAAV5 in the rat striatum
por: Osting, Sue, et al.
Publicado: (2014) -
rAAV8 and rAAV9-Mediated Long-Term Muscle Transduction with Tacrolimus (FK506) in Non-Human Primates
por: Ishii, Akiko, et al.
Publicado: (2020) -
Extracorporeal Delivery of rAAV with Metabolic Exchange and Oxygenation
por: Bieber, Scott, et al.
Publicado: (2013)